Kylie Garbe
Nurse Practitioner · Olney, ILNPI 1932684313
Payments from drug & device makers
Across 80 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$414
- AbbVie$330
- Novo Nordisk$197
- Dexcom, Inc.$83
- Johnson & Johnson$82
- Pfizer$50
- plus $374 from 14 others
What the payments were for
- Food & beverage$1,529100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $414 |
| AbbVie | 20 | $330 |
| Novo Nordisk | 12 | $197 |
| Dexcom, Inc. | 3 | $83 |
| Johnson & Johnson | 5 | $82 |
| Pfizer | 3 | $50 |
| Amgen | 3 | $45 |
| Lilly USA, LLC | 3 | $43 |
| Agile Therapeutics, Inc. | 2 | $38 |
| Viatris Specialty LLC | 2 | $35 |
| GSK | 2 | $31 |
| Mylan Specialty L.p. | 2 | $31 |
| Bayer | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Alvogen Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Corium, LLC | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$116
How this compares
$1,529 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $33,998 |
| MounjaroTirzepatide | 32 | $30,983 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $30,197 |
| JanuviaSitagliptin Phosphate | 19 | $16,077 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,526 |
| Gabapentin | 110 | $1,822 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,383 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,002 |
| Omeprazole | 72 | $617 |
| Potassium Chloride | 50 | $612 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $436 |
| Fluticasone Propionate | 56 | $398 |
| Mirtazapine | 27 | $378 |
| Atorvastatin Calcium | 72 | $356 |
| Tramadol Hcl | 89 | $331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta | $31 | $34,72360 claims |
| Novo NordiskOzempic | $197 | $33,99831 claims |
| Lilly USA, LLCMounjaro | $43 | $30,98332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.
Other nurse practitioner in Olney
- Erika VuckoChicago$417K
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Kristy LukeChicago$77K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
- Dara McKinleyEvanston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.